Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...
Pfizer suffered a blow earlier this month when new data showed that its gene therapy for Duchenne muscular dystrophy failed ...
Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the ...
Catalent, Inc. (CTLT) said, following the closing of transaction, as a private company under Novo Holdings' ownership, Catalent will ...
Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to ...
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback